.jpg)
1 hour ago
3
Article content
VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company developing novel drugs that reprogram and redirect immune cells to fight cancer, is pleased to announce that it has been invited to pitch at CSE Capital Tech Connect, an exclusive event hosted by the Canadian Securities Exchange (CSE) during Web Summit Vancouver.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
During the event, ME Therapeutics’s CEO Dr. Salim Dhanji will join other innovators from public and pre-public technology companies, who will deliver fast-paced presentations on their innovations, current momentum and capital market opportunity.
Article content
Article content
Article content
Dr. Dhanji will briefly highlight how ME Therapeutics’s in vivo immune reprogramming approaches represent the next wave of cancer medicines developed to overcome two major challenges preventing anti-cancer immunity: the highly suppressive tumour environment in many solid tumours and the lack of sufficient tumour-specific immune cells. These approaches include targeted expression of key proteins that can overcome the suppressive tumour microenvironment and reprogramming immune cells in vivo with chimeric antigen receptors (CARs) to directly recognize and kill cancer cells. The pitch will cover high-level insights into ME Therapeutics’s science and corporate strategy.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“It is an honour to be invited by CSE to present our differentiated science, exciting progress to date and investment opportunity,” said Dr. Dhanji. “Activity in the immune reprogramming market continues to accelerate, and ME Therapeutics is at the forefront of this field. We have deep expertise in immune system biology, strategic collaborations with world-class delivery partners, and clinically-tested assets like our CD22 nanobody-based binder. Together, these strengths position us to advance next-generation therapies and expand access to novel cancer therapies for patients.”
Article content
The event will be held on Wednesday, May 13 at The Stack.
Article content
About ME Therapeutics
Article content
Myeloid Enhancement (ME) Therapeutics is a publicly listed biotechnology company based in Vancouver focused on developing novel therapeutics designed to
Article content
Article content
reprogram immune cells in vivo to reshape the tumour microenvironment and to recognize and kill cancer cells
Article content
.
Article content
For more information, visit
Article content
Article content
.
Article content
Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Company: Salim Dhanji, PhD, [email protected], +1-236-516-7714
Media: Claire Piech, [email protected], +1-604-698-6637
Article content
English (US)